Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo, said: "Treating EGFR-mutated non-small cell lung cancer is incredibly challenging following disease progression given that the complexity and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback